Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018226721) COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS USING A GSK-3 INHIBITOR
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2018/226721 International Application No.: PCT/US2018/036101
Publication Date: 13.12.2018 International Filing Date: 05.06.2018
IPC:
A61K 31/433 (2006.01) ,A61P 31/18 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
433
Thiadiazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
14
for RNA viruses
18
for HIV
Applicants:
THE J. DAVID GLADSTONE INSTITUTES [US/US]; 1650 Owens Street San Francisco, California 94158, US
Inventors:
GRAMATICA, Andrea; US
GREENE, Warner C.; US
Agent:
RUBIN, Michael B.; US
Priority Data:
62/515,94306.06.2017US
Title (EN) COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS USING A GSK-3 INHIBITOR
(FR) COMPOSITIONS ET MÉTHODES DE RÉACTIVATION D'UN VIRUS D'IMMUNODÉFICIENCE LATENT AU MOYEN D'UN INHIBITEUR DE GSK-3
Abstract:
(EN) The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus using a glycogen synthase kinase 3α inhibitor, such as a glycogen synthase kinase 3α (GSK-3α) or a glycogen synthase kinase 3β (GSK-3β ) inhibitor. In some embodiments, the glycogen synthase kinase 3 inhibitor is a glycogen synthase kinase antagonist, e.g., Tideglusib (4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione), or a pharmaceutically acceptable salt or derivative thereof. In other embodiments, the glycogen synthase kinase 3 inhibitor is a maleimide-based glycogen synthase kinase 3 inhibitor, e.g., SB-216763 (3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione) or a pharmaceutically acceptable salt or derivative thereof..
(FR) La présente divulgation concerne des compositions et des méthodes de réactivation d'un virus de l'immunodéficience latent à l'aide d'un inhibiteur de glycogène synthase kinase 3α, tel qu'un inhibiteur de glycogène synthase kinase 3α (GSK-3α) ou de glycogène synthase kinase 3β (GSK-3β). Dans certains modes de réalisation, l'inhibiteur de glycogène synthase kinase 3 est un antagoniste de glycogène synthase kinase, p. ex., le Tidéglusib (4-benzyl-2-(naphtalén-1-yl) -1,2,4-thiadiazolidine-3,5-dione), ou un sel ou dérivé pharmaceutiquement acceptable de celui-ci. Dans d'autres modes de réalisation, l'inhibiteur de glycogène synthase kinase 3 est un inhibiteur de glycogène synthase kinase 3 à base de maléimide, p. ex., SB-216763 (3-(2,4-dichlorophényl)-4-(1-méthyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione) ou un sel ou dérivé pharmaceutiquement acceptable de celui-ci.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)